Literature DB >> 1698532

Effect of 5-aza-2'-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells.

R L Momparler1, B T Doré, L F Momparler.   

Abstract

The antineoplastic effects of 5-aza-2'-deoxycytidine (5-AZA-CdR) and retinoic acid on human HL-60 myeloid leukemic cells were investigated. 5-AZA-CdR or retinoic acid reduced the clonogenicity and induced the differentiation of HL-60 leukemic cells. The effects produced by 5-AZA-CdR and retinoic acid in combination on clonogenicity and differentiation of HL-60 leukemic cells were additive. These agents in combination also produced an additive decrease in the mRNA expression of the c-myc. These data indicate that 5-AZA-CdR and retinoic acid in combination produce an additive antineoplastic effect against HL-60 human myeloid leukemic cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698532     DOI: 10.1016/0304-3835(90)90086-d

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.

Authors:  Michael Lübbert; Björn H Rüter; Rainer Claus; Claudia Schmoor; Mathias Schmid; Ulrich Germing; Andrea Kuendgen; Volker Rethwisch; Arnold Ganser; Uwe Platzbecker; Oliver Galm; Wolfram Brugger; Gerhard Heil; Björn Hackanson; Barbara Deschler; Konstanze Döhner; Anne Hagemeijer; Pierre W Wijermans; Hartmut Döhner
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

2.  Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.

Authors:  Noël J-M Raynal; Elodie M Da Costa; Justin T Lee; Vazganush Gharibyan; Saira Ahmed; Hanghang Zhang; Takahiro Sato; Gabriel G Malouf; Jean-Pierre J Issa
Journal:  Mol Cancer Ther       Date:  2016-12-15       Impact factor: 6.261

3.  NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia.

Authors:  Jessica N Nichol; Matthew D Galbraith; Claudia L Kleinman; Joaquín M Espinosa; Wilson H Miller
Journal:  Cell Rep       Date:  2016-03-17       Impact factor: 9.423

4.  Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance.

Authors:  Suzan McNamara; Hongling Wang; Nessrine Hanna; Wilson H Miller
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

Review 5.  Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia.

Authors:  J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

6.  The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation.

Authors:  Ruth Meier; Gabriele Greve; Dennis Zimmer; Helena Bresser; Bettina Berberich; Ralitsa Langova; Julia Stomper; Anne Rubarth; Lars Feuerbach; Daniel B Lipka; Joschka Hey; Björn Grüning; Benedikt Brors; Justus Duyster; Christoph Plass; Heiko Becker; Michael Lübbert
Journal:  Blood Cancer J       Date:  2022-08-22       Impact factor: 9.812

7.  Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.

Authors:  Maryse Lemaire; Guy G Chabot; Noël Jm Raynal; Louise F Momparler; Annie Hurtubise; Mark L Bernstein; Richard L Momparler
Journal:  BMC Cancer       Date:  2008-05-02       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.